SELLAS Life Sciences Group Inc
SLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.33B
Close$
$0.65
92.1% downside
Current Fair Value
92.1% downsideOvervalued by 92.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.33 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 2.24 |
| Outstanding Shares | 172,481,541 |
Return
| Return on Equity | -27.42% |
|---|---|
| Return on Assets | -25.80% |
| Return on Invested Capital | -28.68% |
Valuation & Multiples
| P/E Ratio | -54.51 |
|---|---|
| PEG | -122.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -39.48 |
| Enterprise Value to Net Income | -42 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1677▲ 0.20% |
|---|---|
| Total Calls | 13,460,258▲ 29.61% |
| Total Puts | 2,257,500▲ 31.20% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 49.48%▲ 16.77% |
|---|---|
| Total Invested | $228.42M▲ 70.81% |
| Investors Holding | 175▲ 46.00% |
ESG Score
No data
About SELLAS Life Sciences Group Inc
7 employeesSELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Ketteri...